Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the Investors section of the company website.
Investors can access the webcast at https://investors.rapportrx.com for live viewing and later replay.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RAPP gained 3.35%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RAPP is down 6.76% with several biotech peers also lower: ELVN -5.49%, MAZE -5.07%, ORIC -10.07%, TRVI -2.42%, and DNTH -0.19%, suggesting broader sector weakness alongside company-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Clinical data update | Positive | +2.6% | Strong Phase 2a RAP-219 efficacy and tolerability data in focal onset seizures. |
| Nov 25 | Clinical data preview | Positive | +0.9% | Announcement of upcoming detailed RAP-219 Phase 2a presentations at AES. |
| Nov 06 | Earnings and update | Positive | -3.1% | Q3 financials, positive RAP-219 topline data, and capital raise details. |
| Nov 05 | Investor conferences | Neutral | -3.1% | Planned participation in Stifel and Jefferies healthcare investor conferences. |
| Sep 11 | Investor conference | Neutral | +2.4% | Planned fireside chat at TD Cowen’s neuropsychiatry & epilepsy summit. |
RAPP has generally reacted positively or modestly to clinical and conference news, with one notable divergence on earnings tied to financing and pipeline updates.
Over the last six months, Rapport Therapeutics has highlighted RAP-219’s Phase 2a efficacy data, conference participation, and financing progress. On Nov 6, 2025, Q3 results and a business update, including positive RAP-219 data and a completed public offering, coincided with a -3.1% move. Subsequent AES data on Dec 5, 2025 showing strong seizure reduction produced a +2.64% reaction. Prior conference participation in September and November saw modest moves, framing today’s J.P. Morgan conference notice within a pattern of steady investor-relations activity.
Regulatory & Risk Context
An effective Form S-3 shelf registers 470,589 existing shares for resale from a prior $8 million private placement. The filing is described as administrative, enables a venture investor to sell without creating new shares, and states the company receives no proceeds while covering about $80,000 in registration costs.
Market Pulse Summary
This announcement highlights Rapport’s upcoming presentation at the J.P. Morgan Healthcare Conference on January 14, 2026, extending a steady cadence of investor-facing events following recent RAP-219 data disclosures and financial updates. Investors may track how management frames trial progress, capital position, and timelines versus prior communications. Existing SEC filings, including an effective resale shelf and recent 10b5-1 insider sales, provide additional context on ownership dynamics and potential secondary liquidity.
AI-generated analysis. Not financial advice.
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.
A live and archived webcast of the presentation will be available in the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When will Rapport Therapeutics (RAPP) present at the J.P. Morgan Healthcare Conference?
How can investors watch Rapport Therapeutics (RAPP) presentation on January 14, 2026?
What topics will Rapport Therapeutics (RAPP) cover at the 44th J.P. Morgan Healthcare Conference?
Will Rapport Therapeutics (RAPP) make the presentation replay available after the conference?
Where is the webcast for Rapport Therapeutics (RAPP) hosted?
